Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a...  More >>

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
- Launch Preparation Underway for Lonafarnib in Progeria - Market Development Activities Advancing for HDV Program PALO ALTO, Calif. , Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and
Toggle Summary Eiger Updates on 2019 Progress and 2020 Milestones Expected
- Progeria Rolling NDA Planned for Completion in 1Q 2020 - HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020 - Commercial Focus on Progeria Launch Preparation and HDV Market Building - Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020 PALO ALTO, Calif. , Jan.
Toggle Summary Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
- Rolling NDA Submission Planned for Completion in First Quarter 2020 - Marketing Authorization Application (MAA) to EMA Planned in First Quarter 2020 PALO ALTO, Calif. , Dec. 16, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late stage clinical biopharmaceutical company
Toggle Summary Eiger to Present at Jefferies 2019 London Healthcare Conference
PALO ALTO, Calif. , Nov. 15, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies
Upcoming EventsMore >>
More events are coming soon.
What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.